To investigate the relationship between Leucine-rich repeat G-protein coupled receptor 5 (Lgr5) expression and clinicopathological features of colorectal cancer and its diagnostic and prognostic values.
The cancer and adjacent tissues of 98 patients with colorectal cancer undergoing resection in Jiangsu Cancer Hospital from 2011 to 2013 were enrolled. The intestinal mucosal tissue of 50 healthy subjects was enrolled as a control group. Western blot was used to detect the expression level of Lgr5 in colorectal cancer, Kaplan-Meier method to analyze the correlation of Lgr5 expression with the 5-year survival rate, Cox regression to analyze prognostic risk factors for the patients, and receiver operating characteristics (ROC) curve to analyze the diagnostic value of Lgr5 of the disease.
The expression level of Lgr5 in the intestinal mucosal and adjacent tissues was significantly lower than that in the cancer tissue (p<0.05). The 5-year survival in the Lgr5 low expression group was higher than that in the Lgr5 high expression group (p=0.002). AZD9291 in vitro Lgr5 was an independent risk factor for the prognosis of colorectal cancer. The sensitivity, specificity and the area under the curve (AUC) of Lgr5 were 90.00%, 79.59% and 0.880, respectively (p<0.001).
Patients with a low 5-year survival rate have a high expression of Lgr5, which is closely related to the clinical staging, differentiation, depth of infiltration, lymph node metastasis, vascular invasion, liver metastasis and distant metastasis. Lgr5 is an independent prognostic risk factor for the patients and a better indicator for the diagnosis of colorectal cancer.
Patients with a low 5-year survival rate have a high expression of Lgr5, which is closely related to the clinical staging, differentiation, depth of infiltration, lymph node metastasis, vascular invasion, liver metastasis and distant metastasis. Lgr5 is an independent prognostic risk factor for the patients and a better indicator for the diagnosis of colorectal cancer.
Small cell lung cancer (SCLC) patients unresponsive or relapsing within 90 days following frontline chemotherapy have poor prognosis and they should be treated with different chemotherapy regimens other than those used in the first-line regimen. Currently there is no globally accepted standard chemotherapeutic regimen for the treatment of these patients. This retrospective study was designed to compare CAV (Cyclophosphamide, Doxorubicin, Vincristine), weekly topotecan and weekly irinotecan regimens and to evaluate the efficacy of the three regimens in patients with chemotherapy resistant/refractory (CRR) SCLC.
A total of 67 CRR-SCLC patients, who were treated with CAV, weekly topotecan and weekly irinotecan were reviewed for weekly irinotecan (27 for 60 mg/m2 intravenously on days 1, 8 and 15 of a 28-day cycle,24 for CAV (Cyclophosphamide 750 mg/m² on day 1, Doxorubicin 50 mg/m² on day 1 and Vincristine 1.4mg/m2 on day 1 every 3 weeks), 16 for weekly topotecan (4 mg/m2 intravenously on days 1, 8 and 15 of a 28-day cycle).
The median follow-up time was 12.45 months, there was no difference about disease control rates (DCR) between three chemotherapy regimens (DCR; 25.9% with irinotecan, 29.2% with CAV and 31.3% with topotecan, p=0.92). Objective response rates (ORR) for irinotecan, CAV and topotecan groups were 3,7%, 8,8%, and 0%, respectively (p=0.63). Median progression free survival (PFS) and overall survival (OS) were similar according to irinotecan, CAV, and topotecan (PFS 1.93 months, 2.30 months and 3.45 months; OS 2.89 months, 4.79 months and 5.81 months, respectively). The adverse events were generally mild and manageable for both hematological and nonhematological toxicities in all three arms.
Weekly irinotecan, CAV and weekly topotecan are similarly effective and safe chemotherapy protocols for the treatment of CRR-SCLC patients.
Weekly irinotecan, CAV and weekly topotecan are similarly effective and safe chemotherapy protocols for the treatment of CRR-SCLC patients.
To explore the efficacy and safety of 125 I radioactive seed implantation combined with intermittent hormonal therapy (IHT) in the clinical treatment of moderate- and high-risk non-metastatic prostate cancer.
A total of 136 patients were divided into the observation group (n=68) and the control group (n=68). In the observation group, 125I radioactive seed implantation was performed, bicalutamide capsules were taken orally immediately after operation, and leuprorelin was injected from 1 week after operation. In the control group, IHT alone was administered. The level of serum prostate specific antigen (PSA), maximum urine flow rate (Q max ) and international prostate symptom scale (IPSS) score were compared between the two groups before and after treatment. Moreover, the overall survival (OS), tumor-specific survival (TSS), distant metastasis-free survival (DMFS) and progression-free survival (PFS) of patients were recorded.
There were no statistically significant differences in the PSA level, Q max and rol group (p=0.037, p=0.022).
125 I seed implantation combined with IHT is safe and effective in the clinical treatment of patients with moderate- and high-risk non-metastatic prostate cancer. Compared with the IHT alone, the combination therapy can significantly prolong the intermission time of hormonal therapy and effectively control the progression of disease.
125 I seed implantation combined with IHT is safe and effective in the clinical treatment of patients with moderate- and high-risk non-metastatic prostate cancer. Compared with the IHT alone, the combination therapy can significantly prolong the intermission time of hormonal therapy and effectively control the progression of disease.
To investigate the expressions of CD44 non-small cell lung cancer cells, proliferating cell nuclear antigen (PCNA) and multidrug resistance-associated protein 1 (MRP1) in the lung cancer tissues and their effects on the proliferation and invasion abilities in vitro of lung cancer cell line 95D.
138 lung cancer tissues and 127 adjacent normal tissues were collected from lung cancer patients after operation in Shandong Provincial Third Hospital from January 2015 to December 2017. CD44 siRNA (experimental CD44 group), PCNA siRNA (experimental PCNA group) and MRP1 siRNA (experimental MRP1 group) were transfected into human lung cancer 95D cells, and a negative control group (cells transfected with miR-Native Control) and a blank group (untransfected cells) were established. MTT assay was used for detecting the proliferation of cells, and Transwell chamber was used for detecting their invasion ability.
The relative expressions of CD44, PCNA and MRP1 in the lung cancer tissues were higher than those in the adjacent tissues (p<0.AZD9291 in vitro
Top comments (0)